HematologyNews.net

Hematology Xagena

Data from a secondary analysis of the pivotal phase 3 ASPIRE trial that showed Carfilzomib ( Kyprolis ) for injection in combination with Lenalidomide ( Revlimid ) and Dexamethasone ( KRd) improved pr ...


The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin l ...


The results from the pivotal phase III GALLIUM trial in people with previously untreated follicular lymphoma, the most common type of indolent ( slow-growing ) non-Hodgkin lymphoma ( iNHL ), were anno ...


Despite new therapies, multiple myeloma remains incurable causing most patients to ultimately develop drug resistance and succumb to the disease. The pursuit of drugs that inhibit cell cycle regulator ...


Researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival. The findings which appear in the j ...


A new analysis has indicated that higher body weight and taller stature during adolescence increase the risk of developing non-Hodgkin's lymphoma ( NHL ), a type of cancer of the lymphatic system. T ...


Mantle cell lymphoma ( MCL ) is an aggressive lymphoma with a dismal prognosis because of numerous relapses. Because the most promising results have been obtained with immunochemotherapy followed by ...


The results of the phase II TITAN study with Caplacizumab for patients with acquired thrombotic thrombocytopenic purpura ( aTTP) have been published in The New England Journal of Medicine ( NEJM ). ...


Positive results from the global phase III RATIFY ( CALGB 10603 ) clinical trial were announced. In the study, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leuk ...


A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma ( DLBCL ) are more likely to respond to the drug Ibrutinib ( Imbruvica ) than patients with ...


The benefit of Azacitidine treatment in survival of high-risk myelodysplastic syndromes ( MDS ) patients compared with conventional care treatment ( CCT ) has not been established outside clinical tri ...


Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( ...


A phase 2 trial of the investigational medicine Venetoclax met its primary endpoint ( overall response rates ) in patients with relapsed / refractory or previously untreated chronic lymphocytic leukem ...


PF-05082566 ( PF-2566 ) is an investigational immunotherapy and fully humanized monoclonal antibody administered intravenously that stimulates signaling through 4-1BB ( CD-137 ), a protein expressed i ...


Results from a sub-analysis of the phase 2 RESONATE-17 study has shown Ibrutinib ( Imbruvica ) was associated with robust efficacy and a positive risk-benefit profile in patients with relapsed or refr ...


Initial treatment of acute promyelocytic leukaemia traditionally involves Tretinoin ( all-trans retinoic acid ) combined with anthracycline-based risk-adapted chemotherapy, with Arsenic trioxide being ...


Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Lenalidomide a ...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as Crizot ...


Positive top-line results of the Kids B-LONG phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [ Coagulation Factor IX ( Recombinant ), Fc Fusion Protein ] in ...


Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia ( CLL ) responded to the therapy, with some complete remissio ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...


Vitamin D is increasingly recognized for its roles in non-skeletal disorders. Patients with sickle cell disease ( SCD ) have a high prevalence of vitamin D deficiency but data are limited with respect ...


The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell pre ...


Data from the largest clinical trial of myelofibrosis patients treated with Ruxolitinib ( Jakavi ) were presented at 56th Annual Meeting of the American Society of Hematology ( ASH ) in San Francisco ...


The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. Researchers hypothesized that such mutations would be detect ...


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients treated with ISIS-FXI Rx undergoing total knee replacement surgery, o ...


The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst ) plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


Positive results from a cohort of patients in its ongoing phase 1b trial ( CheckMate-039 ) which evaluated PD-1 immune checkpoint inhibitor, Nivolumab ( Opdivo), in patients with relapsed or refractor ...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively. Platelets have a role in venous thromboe ...


Chronic ophthalmological complications of SCD include proliferative sickle retinopathy ( PSR ) and vitreous hemorrhage. They occur in up to 50% of individuals with SCD, and are found more frequently ...


Positive results of the Kids A-LONG phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in childr ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Chronic kidney disease ( CKD ) is defined as either having a glomerular filtration rate ( GFR ) of less than 60 mL/min/1.73 mL for more than 3 months with or without kidney damage or having evidence o ...


Ultrasound-guided foam sclerotherapy and endovenous laser ablation are widely used alternatives to surgery for the treatment of varicose veins, but their comparative effectiveness and safety remain un ...


Data from FIRST, an open-label phase III randomized study of continuous Lenalidomide ( Revlimid ) in combination with Dexamethasone in patients newly diagnosed with multiple myeloma ( NDMM ) who are n ...


Pulmonary hypertension ( PH ) is defined as an elevation of the resting mean pulmonary arterial pressure ( greater than or equal to 25 mmHg ) as determined by right heart catheterization ( RHC ). Th ...


Leg ulcers are a common complication of sickle cell disease ( SCD ) in general and sickle-cell anaemia ( SCA ) in particular. Leg ulceration was reported in all of the first four people with sickle ce ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Avascular necrosis ( AVN, also known as aseptic necrosis, osteonecrosis, or ischemic necrosis ) is bone death due to compromised blood supply. Necrosis can occur when capillaries are occluded by sic ...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...


In sickle cell disease ( SCD ), pain is considered chronic if it lasts more than 3 months. People with sickle cell disease experience both nociceptive and neuropathic pain. Nociceptive pain is a hallm ...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review of Iclusig ( Ponatinib ) under the Article 20 referral procedure and has reco ...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


Intravenous Rituximab ( MabThera, Rituxan ) is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent Rituximab serum concentrations might improve conveni ...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat ( Zolinza ) is an inhibitor of histone deac ...


Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints migh ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati